- Home
- UHG vs MDAIW Comparison
UHG vs MDAIW Comparison
Compare UHG & MDAIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UHG | MDAIW |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | 78 |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.7M | N/A |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UHG | MDAIW |
|---|---|---|
| Price | $1.32 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 147.2K | 35.6K |
| Earning Date | 11-06-2025 | 02-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,113,017.00 | $27,264,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 44.52 |
| 52 Week Low | $0.99 | $0.08 |
| 52 Week High | $4.81 | $0.90 |
Technical Indicators
Market Signals| Indicator | UHG | MDAIW |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 48.02 |
| Support Level | $1.12 | $0.45 |
| Resistance Level | $1.24 | $0.60 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.10 | 0.02 |
| Stochastic Oscillator | 71.08 | 59.21 |
Price Performance
Historical ComparisonAbout UHG United Homes Group Inc
United Homes Group Inc operates as a homebuilder which operates with a land-light idea in the Southeast. The company currently has a presence in South Carolina, North Carolina, and Georgia and focuses on providing high-quality, affordable homes for the entry-level and first-move-up segments. The company has three reportable segments: GSH South Carolina, Rosewood, and Other.
About MDAIW Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.